PL2411394T3 - Użyteczne sole farmaceutyczne 7-[(3r, 4r)-3-hydroksy-4-hydroksymetylopirolidyn-1-ylometylo]-3,5-dihydropirolo[3,2-d]pirymidyno-4-nu - Google Patents
Użyteczne sole farmaceutyczne 7-[(3r, 4r)-3-hydroksy-4-hydroksymetylopirolidyn-1-ylometylo]-3,5-dihydropirolo[3,2-d]pirymidyno-4-nuInfo
- Publication number
- PL2411394T3 PL2411394T3 PL10756789T PL10756789T PL2411394T3 PL 2411394 T3 PL2411394 T3 PL 2411394T3 PL 10756789 T PL10756789 T PL 10756789T PL 10756789 T PL10756789 T PL 10756789T PL 2411394 T3 PL2411394 T3 PL 2411394T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- pyrrolidin
- pyrimidin
- ylmethyl
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16280509P | 2009-03-24 | 2009-03-24 | |
| EP10756789.3A EP2411394B1 (en) | 2009-03-24 | 2010-03-24 | Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one |
| PCT/US2010/028490 WO2010111381A2 (en) | 2009-03-24 | 2010-03-24 | Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2411394T3 true PL2411394T3 (pl) | 2015-01-30 |
Family
ID=42781851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10756789T PL2411394T3 (pl) | 2009-03-24 | 2010-03-24 | Użyteczne sole farmaceutyczne 7-[(3r, 4r)-3-hydroksy-4-hydroksymetylopirolidyn-1-ylometylo]-3,5-dihydropirolo[3,2-d]pirymidyno-4-nu |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8501753B2 (pl) |
| EP (1) | EP2411394B1 (pl) |
| JP (1) | JP5766687B2 (pl) |
| KR (1) | KR101763672B1 (pl) |
| CN (1) | CN102448963B (pl) |
| AU (1) | AU2010230008B2 (pl) |
| BR (1) | BRPI1006534B1 (pl) |
| CA (1) | CA2755950C (pl) |
| EA (1) | EA020931B1 (pl) |
| ES (1) | ES2519568T3 (pl) |
| HK (1) | HK1170486A1 (pl) |
| IL (1) | IL215298A (pl) |
| MX (1) | MX2011009928A (pl) |
| NZ (1) | NZ595590A (pl) |
| PL (1) | PL2411394T3 (pl) |
| RU (1) | RU2489435C2 (pl) |
| SG (1) | SG174517A1 (pl) |
| WO (1) | WO2010111381A2 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2937350T1 (en) | 2008-04-23 | 2018-05-31 | Gilead Sciences, Inc. | 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT |
| US10023600B2 (en) | 2009-09-21 | 2018-07-17 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs |
| EP2805960A1 (en) | 2010-07-19 | 2014-11-26 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| BR112018005048B8 (pt) | 2015-09-16 | 2021-03-23 | Gilead Sciences Inc | uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae |
| AU2018235754B2 (en) | 2017-03-14 | 2021-04-08 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| WO2021183750A2 (en) | 2020-03-12 | 2021-09-16 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
| CN115666570A (zh) | 2020-05-29 | 2023-01-31 | 吉利德科学公司 | 瑞德西韦治疗方法 |
| EP4172160A2 (en) | 2020-06-24 | 2023-05-03 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| CA3190702A1 (en) | 2020-08-27 | 2022-03-03 | Elaine Bunyan | Compounds and methods for treatment of viral infections |
| KR102580079B1 (ko) * | 2020-10-29 | 2023-09-19 | 한양대학교 산학협력단 | 기생 인덕턴스 감소를 위한 적층형 회로 구조체 |
| GB202110403D0 (en) * | 2021-07-20 | 2021-09-01 | Laevoroc Immunology | Ulodesine Salt |
| TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| GB202218782D0 (en) | 2022-12-13 | 2023-01-25 | Mehrling Thomas | Purine nucleoside phosphorylase inhibitor for metabolic syndrome |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870732A (en) | 1973-08-21 | 1975-03-11 | Velsicol Chemical Corp | Mixed salts of aluminum |
| US5386031A (en) * | 1993-12-15 | 1995-01-31 | Warner-Lambert Company | Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones |
| BR9809178A (pt) * | 1997-05-29 | 2000-08-01 | Novartis Ag | 2-amino-7-(1-substituìdo-2-hidroxietil)-3,5-dihidro-pir rolo[3,2-d]pirimidin-4-onas |
| CN100379750C (zh) * | 2002-08-21 | 2008-04-09 | 阿尔伯爱因斯坦医科叶希瓦大学 | 核苷磷酸化酶和核苷酶抑制剂 |
| NZ523970A (en) * | 2003-02-04 | 2005-02-25 | Ind Res Ltd | Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
-
2010
- 2010-03-24 WO PCT/US2010/028490 patent/WO2010111381A2/en active Application Filing
- 2010-03-24 PL PL10756789T patent/PL2411394T3/pl unknown
- 2010-03-24 NZ NZ595590A patent/NZ595590A/xx unknown
- 2010-03-24 SG SG2011068608A patent/SG174517A1/en unknown
- 2010-03-24 US US13/258,497 patent/US8501753B2/en active Active
- 2010-03-24 EA EA201190205A patent/EA020931B1/ru unknown
- 2010-03-24 BR BRPI1006534-2A patent/BRPI1006534B1/pt active IP Right Grant
- 2010-03-24 ES ES10756789.3T patent/ES2519568T3/es active Active
- 2010-03-24 JP JP2012502204A patent/JP5766687B2/ja active Active
- 2010-03-24 CA CA2755950A patent/CA2755950C/en active Active
- 2010-03-24 KR KR1020117024909A patent/KR101763672B1/ko active IP Right Grant
- 2010-03-24 EP EP10756789.3A patent/EP2411394B1/en active Active
- 2010-03-24 MX MX2011009928A patent/MX2011009928A/es active IP Right Grant
- 2010-03-24 CN CN201080022925.6A patent/CN102448963B/zh active Active
- 2010-03-24 RU RU2011141212/04A patent/RU2489435C2/ru active
- 2010-03-24 AU AU2010230008A patent/AU2010230008B2/en active Active
-
2011
- 2011-09-22 IL IL215298A patent/IL215298A/en active IP Right Grant
-
2012
- 2012-11-07 HK HK12111259.9A patent/HK1170486A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2755950C (en) | 2017-04-25 |
| CA2755950A1 (en) | 2010-09-30 |
| CN102448963B (zh) | 2015-06-17 |
| AU2010230008B2 (en) | 2015-06-04 |
| BRPI1006534A2 (pt) | 2016-08-02 |
| KR20120005466A (ko) | 2012-01-16 |
| JP2012521992A (ja) | 2012-09-20 |
| RU2011141212A (ru) | 2013-04-27 |
| US20120165526A1 (en) | 2012-06-28 |
| EP2411394A4 (en) | 2012-08-15 |
| SG174517A1 (en) | 2011-10-28 |
| RU2489435C2 (ru) | 2013-08-10 |
| ES2519568T3 (es) | 2014-11-07 |
| KR101763672B1 (ko) | 2017-08-01 |
| AU2010230008A1 (en) | 2011-10-06 |
| BRPI1006534B1 (pt) | 2021-05-25 |
| US8501753B2 (en) | 2013-08-06 |
| IL215298A (en) | 2017-04-30 |
| CN102448963A (zh) | 2012-05-09 |
| JP5766687B2 (ja) | 2015-08-19 |
| MX2011009928A (es) | 2012-03-16 |
| EA020931B1 (ru) | 2015-02-27 |
| EP2411394B1 (en) | 2014-08-06 |
| WO2010111381A3 (en) | 2011-03-31 |
| HK1170486A1 (en) | 2013-03-01 |
| WO2010111381A2 (en) | 2010-09-30 |
| EP2411394A2 (en) | 2012-02-01 |
| NZ595590A (en) | 2013-11-29 |
| EA201190205A1 (ru) | 2012-06-29 |
| IL215298A0 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2411394T3 (pl) | Użyteczne sole farmaceutyczne 7-[(3r, 4r)-3-hydroksy-4-hydroksymetylopirolidyn-1-ylometylo]-3,5-dihydropirolo[3,2-d]pirymidyno-4-nu | |
| EP2491043A4 (en) | 2,7-SUBSTITUTED THIEN [3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | |
| IL248246A0 (en) | (5r,2s)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (5r,2s)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of anti-infective drugs | |
| ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| IL211191A (en) | Oxalate salt of (3as, 4r, 6s, 6ar) –6– (2– hydroxyethoxy) –2,2 – dimethyl tetrahydro –3 ah– cyclopenta [d] [1,3] dioxol – 4 – amine | |
| ZA201306545B (en) | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of betasecretase (bace) | |
| IL228590A0 (en) | History of pyrrolo[3,2-d] pyrimidine as inhibitors of tropomyosin-linked kinases | |
| PT3012258T (pt) | Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral | |
| HK1160116A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds [23-d] | |
| ZA201202718B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| HK1170241A1 (zh) | 可用作 的抑制劑的化合物的製備方法 | |
| ZA201105896B (en) | [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors | |
| IL218032A0 (en) | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors | |
| HK1201441A1 (en) | Process for the preparation of substituted pyrimidine derivatives | |
| HK1177207A1 (en) | 5-oxo-5, 8-dihydropyrido [2, 3-d]pyrimidine derivatives as camkii kinases inhibitors for the treatment of cardiovascular diseases camkii 5--58-[23-d] | |
| EP2401278A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF A CARBAPENEM ANTIBIOTICS | |
| IL220448A (en) | Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses | |
| EP2511276A4 (en) | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE | |
| IL215521A0 (en) | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES |